Follow
Michael J. Waring
Michael J. Waring
Verified email at ncl.ac.uk - Homepage
Title
Cited by
Cited by
Year
An analysis of the attrition of drug candidates from four major pharmaceutical companies
MJ Waring, J Arrowsmith, AR Leach, PD Leeson, S Mandrell, RM Owen, ...
Nature reviews Drug discovery 14 (7), 475-486, 2015
13902015
Lipophilicity in drug discovery
MJ Waring
Expert Opinion on Drug Discovery 5 (3), 235-248, 2010
8432010
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor
MRV Finlay, M Anderton, S Ashton, P Ballard, PA Bethel, MR Box, ...
Journal of medicinal chemistry 57 (20), 8249-8267, 2014
5642014
Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease
A Douangamath, D Fearon, P Gehrtz, T Krojer, P Lukacik, CD Owen, ...
Nature communications 11 (1), 5047, 2020
4522020
Defining optimum lipophilicity and molecular weight ranges for drug candidates—molecular weight dependent lower log D limits based on permeability
MJ Waring
Bioorganic & medicinal chemistry letters 19 (10), 2844-2851, 2009
3652009
Structure-and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)
RA Ward, MJ Anderton, S Ashton, PA Bethel, M Box, S Butterworth, ...
Journal of medicinal chemistry 56 (17), 7025-7048, 2013
2702013
Directed dihydroxylation of cyclic allylic alcohols and trichloroacetamides using OsO4/TMEDA
TJ Donohoe, K Blades, PR Moore, MJ Waring, JJG Winter, M Helliwell, ...
The Journal of organic chemistry 67 (23), 7946-7956, 2002
1882002
A quantitative assessment of hERG liability as a function of lipophilicity
MJ Waring, C Johnstone
Bioorganic & medicinal chemistry letters 17 (6), 1759-1764, 2007
1752007
AZD5153: a novel bivalent BET bromodomain inhibitor highly active against hematologic malignancies
GW Rhyasen, MM Hattersley, Y Yao, A Dulak, W Wang, P Petteruti, ...
Molecular cancer therapeutics 15 (11), 2563-2574, 2016
1452016
Potent and selective bivalent inhibitors of BET bromodomains
MJ Waring, H Chen, AA Rabow, G Walker, R Bobby, S Boiko, ...
Nature chemical biology 12 (12), 1097-1104, 2016
1402016
Conversion of α, β-unsaturated ketones into α-hydroxy ketones using an MnIII catalyst, phenylsilane and dioxygen: acceleration of conjugate hydride reduction by dioxygen
P Magnus, AH Payne, MJ Waring, DA Scott, V Lynch
Tetrahedron Letters 41 (50), 9725-9730, 2000
1362000
The directed dihydroxylation of allylic alcohols
TJ Donohoe, PR Moore, MJ Waring, NJ Newcombe
Tetrahedron letters 38 (28), 5027-5030, 1997
1351997
Development of a novel B-cell lymphoma 6 (BCL6) PROTAC to provide insight into small molecule targeting of BCL6
W McCoull, T Cheung, E Anderson, P Barton, J Burgess, K Byth, Q Cao, ...
ACS Chemical Biology 13 (11), 3131-3141, 2018
1342018
FragLites—minimal, halogenated fragments displaying pharmacophore doublets. An efficient approach to druggability assessment and hit generation
DJ Wood, JD Lopez-Fernandez, LE Knight, I Al-Khawaldeh, C Gai, S Lin, ...
Journal of Medicinal Chemistry 62 (7), 3741-3752, 2019
832019
Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3 R)-4-[2-[4-[1-(3-Methoxy-[1, 2, 4] triazolo [4, 3-b …
RH Bradbury, R Callis, GR Carr, H Chen, E Clark, L Feron, S Glossop, ...
Journal of medicinal chemistry 59 (17), 7801-7817, 2016
802016
Conjugate reduction of α, β-unsaturated ketones using an MnIII catalyst, phenylsilane and isopropyl alcohol
P Magnus, MJ Waring, DA Scott
Tetrahedron Letters 41 (50), 9731-9733, 2000
792000
Sequential Double α-Arylation of N-Allylureas by Asymmetric Deprotonation and N→C Aryl Migration
DJ Tetlow, U Hennecke, J Raftery, MJ Waring, DS Clarke, J Clayden
Organic Letters 12 (23), 5442-5445, 2010
712010
Stereoselective synthesis of the bicyclo [5.3. 0] decane portion of the diterpene antibiotic guanacastepene using a pyrylium-ylide [5+ 2] cycloaddition reaction
P Magnus, MJ Waring, C Ollivier, V Lynch
Tetrahedron Letters 42 (30), 4947-4950, 2001
702001
Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors
W McCoull, RD Abrams, E Anderson, K Blades, P Barton, M Box, ...
Journal of Medicinal Chemistry 60 (10), 4386-4402, 2017
692017
Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules
T Luker, L Alcaraz, KK Chohan, N Blomberg, DS Brown, RJ Butlin, ...
Bioorganic & medicinal chemistry letters 21 (19), 5673-5679, 2011
672011
The system can't perform the operation now. Try again later.
Articles 1–20